The verdict
Our read at a glance.
Whether targeting the reward side of eating produces enough weight loss to justify a psychiatric boxed warning.
- The signal
- The phase 3 programme was substantial and consistent, showing greater weight loss than placebo alongside lifestyle intervention, with effect sizes well below those seen with GLP-1 receptor agonists, and registered trials continue across metabolic and behavioural indications. Its cardiovascular outcomes trial has its own history: an interim analysis was released publicly before the trial completed, the sponsor's handling of that disclosure drew regulatory criticism, and the trial was terminated - leaving the cardiovascular safety question less cleanly answered than it should have been.
- The unknown
- Long-term cardiovascular safety, which the terminated outcomes trial was supposed to establish and did not.
- Our read
- A legitimate approved option with a genuinely different mechanism, doing modest work, and carrying psychiatric and seizure warnings that make it a poor default. The outcomes-trial episode is also a reminder that a terminated safety trial leaves a question open rather than answering it favourably.
The mechanism
How it works.
The combination targets two points in the same circuit. Bupropion inhibits reuptake of dopamine and noradrenaline, and it stimulates pro-opiomelanocortin neurons in the hypothalamus, which release alpha-MSH and reduce food intake. Those same neurons also release beta-endorphin, which loops back and inhibits them - a natural brake that limits how much appetite suppression bupropion alone can produce. Naltrexone is an opioid receptor antagonist, and its job in this combination is to block that brake, so the POMC neurons keep firing. The result is a sustained reduction in appetite and in food-related reward signalling, which is why it is described as acting on craving rather than fullness. That reward-pathway mechanism is also why the psychiatric warnings travel with it.
Safety & regulatory boundary
The consequential part.
Approved for chronic weight management with lifestyle modification. It carries a boxed warning for suicidal thoughts and behaviours associated with bupropion, and it lowers the seizure threshold, so it is contraindicated in seizure disorders, uncontrolled hypertension and in abrupt alcohol or benzodiazepine withdrawal. The naltrexone component blocks opioid analgesia, which matters for anyone who may need opioid pain relief. Raised blood pressure and heart rate are common.
What's next
What we're watching.
Any new cardiovascular outcomes data, and how it is positioned as GLP-1 access widens.
Context
Why this is discussed.
It is one of the few approved oral options, it is cheaper than a GLP-1, and it targets craving rather than fullness, which suits people whose problem is not satiety.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE4 · COMPLETED · 2025-07-01
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · ENROLLING_BY_INVITATION · 2020-02-01
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2024-07-01
ClinicalTrials.gov · PHASE1 · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · PHASE1/PHASE2 · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2022-01-13
ClinicalTrials.gov · PHASE4 · RECRUITING · 2023-06-08
Indexed literature (PubMed)12
Drug Ther Bull · Drug Ther Bull · 2017
Elmaleh-Sachs A et al. · JAMA · 2023
Gudzune KA et al. · JAMA · 2024
Apovian CM et al. · Obesity (Silver Spring) · 2013
Barrea L et al. · Minerva Endocrinol · 2020
Apovian CM · Future Cardiol · 2016
Onakpoya IJ et al. · Br J Clin Pharmacol · 2020
Billes SK et al. · Pharmacol Res · 2014
Bray GA et al. · Lancet · 2016
Greig SL et al. · Drugs · 2015
Gadde KM et al. · J Am Coll Cardiol · 2018
Verpeut JL et al. · Expert Opin Drug Saf · 2014
Keep reading